TScan Therapeutics Q4 net loss widens

Tscan Therapeutics

04/03/2026 12:09

Overview

Biotech firm's Q4 collaboration revenue rose significantly yr/yr

Company reported a Q4 net loss

FDA cleared INDs for new TCR-T therapy candidates targeting CD45

Outlook

Company to share early clinical data from ALLOHA study in Q2 2026

TScan to launch pivotal trial for TSC-101 in Q2 2026

Company plans Phase 1 study of TSC-102-A01 and TSC-102-A03 in H2 2026

Result Drivers

ALLOHA TRIAL PROGRESS - Positive data from ALLOHA Phase 1 trial presented at ASH, showing favorable relapse-free and overall survival rates

FDA CLEARANCE - FDA cleared INDs for TSC-102-A01 and TSC-102-A03, expanding heme program to more patients

COHORT C ENROLLMENT - Completed enrollment in Cohort C of ALLOHA trial using commercial-ready manufacturing process

Company press release: ID:nGNX6CWCcz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration and License Revenue
$2.57 mln
Q4 Net Income
-$22.98 mln
Q4 Basic EPS
-$0.18
Q4 Income From Operations
-$23.86 mln
Q4 Operating Expenses
$26.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 479.7% above its March 3 closing price of $1.04

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)